Cresco Labs (CRLBF) Current Deferred Revenue (2020)

Cresco Labs' (CRLBF) quarterly Current Deferred Revenue came in at -$2.9 million in Q4 2020.

Cresco Labs (CRLBF) Current Deferred Revenue (2020) Analysis & Trends

Cresco Labs (CRLBF) has 1 years of Current Deferred Revenue data on file, last reported at -$2.9 million in Q4 2020.

Quarterly Current Deferred Revenue changed N/A year-over-year to -$2.9 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was -$2.9 million (changed N/A YoY) and the FY2020 annual result came in at -$2.9 million, changed N/A from the prior year.
Current Deferred Revenue held at -$2.9 million in Q4 2020.
In the past five years, Current Deferred Revenue ranged from a high of -$2.9 million in Q4 2020 to a low of -$2.9 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-
10	Cresco Labs	295.09 Mn	230.98 Mn	86.95 Mn

Download Data

Date	Value
Dec 31, 2020	-2.92 Mn